Abstract
Objective: To assess the hemostatic efficacy of a new local hemostatic agent, Ankaferd Blood Stopper (ABS), for the control of bleeding following tooth extraction in hemophiliacs.Materials and Methods: Simple tooth extractions were performed in 27 hemophilia A patients. In the treatment group (n=17) local hemostasis was achieved via application of ABS to the extraction sockets, whereas in the control group (n=10) local hemostasis was achieved via direct packing with gauze.Results: In all, 57 (21 primary and 36 permanent) teeth extractions were performed in 27 hemophilia A patients. There were no significant differences in age or factor VIII level distribution between the 2 groups (p>0.05). The most significant clinical difference between the groups was associated with the use of ABS; those in the treatment group had significantly shorter duration of bleeding (p=0.002). Conclusion: This is the first study to evaluate the efficacy of ABS for the control of bleeding following tooth extraction in hemophiliacs. ABS can be considered an alternative local hemostatic agent for reducing clotting factor concentrates in hemophilia patients.Conflict of interest:None declared.
Highlights
Hemophilia is an X-linked hereditary disorder with male predominance and a frequency of approximately 1/10,000 births
This is the first study to evaluate the efficacy of Ankaferd Blood Stopper (ABS) for the control of bleeding following tooth extraction in hemophiliacs
ABS can be considered an alternative local hemostatic agent for reducing clotting factor concentrates in hemophilia patients
Summary
Hemophilia is an X-linked hereditary disorder with male predominance and a frequency of approximately 1/10,000 births. Hemophilia can be classified as severe (
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
